Similar Papers

Paper Title
Journal
Date
Author
Gastrointestinal stromal tumor: Our experience
C Gennaro ... S Sandrucci
European Journal of Surgical Oncology | VOL. 38
C Gennaro, et. al.C Gennaro ... S Sandrucci
15 Sep 2012
Chromosomal complexity as a biomarker to de-escalate adjuvant imatinib treatment in high-risk gastrointestinal stromal tumor.
Kjetil Boye ... Toto Hølmebakk
Journal of Clinical Oncology | VOL. 39
Kjetil Boye, et. al.Kjetil Boye ... Toto Hølmebakk
20 May 2021
The Impact of Narrow Band Imaging in the Detection and Resection of Bladder Tumor in Transitional Cell Carcinoma of the Bladder: A Prospective, Blinded, Sequential Intervention Randomized Controlled Trial
Partho Mukherjee ... Antony Devasia
Urology | VOL. 128
Partho Mukherjee, et. al.Partho Mukherjee ... Antony Devasia
26 Feb 2019
Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients
Tatsuo Kanda ... Yasushi Toh
International Journal of Clinical Oncology | VOL. 18
Tatsuo Kanda, et. al.Tatsuo Kanda ... Yasushi Toh
23 Nov 2011
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Aiming Targeted Drug Development at Rare Pediatric Malignancies
Julia L Glade Bender
Journal of Clinical Oncology | VOL. -
Julia L Glade BenderJulia L Glade Bender
03 Feb 2025
Risk factors for mortality and financial burdens in patients with colon cancer.
Zaid Zahid ... Lisa A Duhaime
Journal of Clinical Oncology | VOL. 43
Zaid Zahid, et. al.Zaid Zahid ... Lisa A Duhaime
01 Feb 2025
Disparities in organ preservation rate for high-risk stage I rectal cancer.
Annmarie Butare ... Michael Honaker
Journal of Clinical Oncology | VOL. 43
Annmarie Butare, et. al.Annmarie Butare ... Michael Honaker
01 Feb 2025
Differences in disease characteristics in young vs older adults with colorectal carcinoma.
Shivani Modi ... Adit Dharia
Journal of Clinical Oncology | VOL. 43
Shivani Modi, et. al.Shivani Modi ... Adit Dharia
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.